Skip to main content
Clinical Trials/ITMCTR2100004992
ITMCTR2100004992
Not yet recruiting
Phase 1

Clinical study on effectiveness and safety of Kunbixiao Decoction optimized by Ersi decoction in the treatment of female rheumatoid arthritis

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Female RA patients who meet the diagnostic criteria of Western medicine and TCM syndrome of ''Toxin Heat Phlegm Stasis Accumulation Syndrome'';
  • 2\. Aged 18\-65 years;
  • 3\. Disease activity score (DAS28\) \> 3\.2 and \<\= 5\.1;
  • 4\. Those who did not participate in any drug trials within 4 weeks before enrollment;
  • 5\. Volunteer subjects and signed informed consent.

Exclusion Criteria

  • 1\. Patients who are pregnant, breastfeeding, planning to become pregnant during treatment and/or within 12 weeks after the end of treatment;
  • 2\. Combined with serious primary diseases such as cardiovascular, liver, kidney and hematopoietic system, mental patients;
  • 3\. Those who have been diagnosed with other connective tissue diseases such as systemic lupus erythematosus, Sj?gren's syndrome, myositis or dermatomyositis;
  • 4\. There are pituitary tumors, hyperthyroidism, ovarian cysts and other diseases affecting endocrine, history of uterine or ovarian surgery, or oral contraceptives within the past 4 weeks;
  • 5\. Those who do not meet the requirements for combined medication;
  • 6\. Those who are known to be allergic to any traditional Chinese medicine used in this test, or allergic constitution (allergic to two or more drugs, food, and pollen).
  • 7\. Those with a history of drug, drug or alcohol abuse;
  • 8\. Other conditions deemed inappropriate by the investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials